A Phase 1 interventional study of Tirabrutinib in Non Hodgkins Lymphoma and Chronic Lymphocytic Leukaemia, sponsored by Gilead Sciences. Completed at 6 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-03-16.
Sponsored by Gilead Sciences · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Lymphoma, Non-Hodgkin by Gilead Sciences — none open to participants now, none under way, none of them phase 3. Lymphoma, Non-Hodgkin · Gilead Sciences.
Among the 21 studies in Lymphoma, Non-Hodgkin by Gilead Sciences, this one is the 6th largest by enrollment of the 20 interventional ones that give a count, is one of 3 that started in 2012, is one of 6 in phase 1, and was the 16th registered.
2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.
Browse Lymphoma, Non-Hodgkin studies →None of the 21 studies in Lymphoma, Non-Hodgkin by Gilead Sciences is open now. The open studies under Lymphoma, Non-Hodgkin, anywhere →
Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 14 · Phase 3 2
First in 1997; this study’s year is marked. 3 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 90 is above the median of 40 across 1,883 interventional studies indexed under Lymphoma, Non-Hodgkin.
Median enrollment 39 across the 20 interventional studies. Of the 18 that completed or were terminated, 6 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 21 studies in Lymphoma, Non-Hodgkin by Gilead Sciences, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is to evaluate the safety and tolerability of tirabrutinib (formerly ONO/GS-4059) given as monotherapy to participants with relapsed/refractory non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL).
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with relapsed/refractory chronic lymphocytic leukaemia (CLL) received tirabrutinib 20 mg once daily.
Drug: Tirabrutinib
Participants with relapsed/refractory CLL received tirabrutinib 40 mg once daily.
Drug: Tirabrutinib
Participants with relapsed/refractory CLL received tirabrutinib 80 mg once daily.
Drug: Tirabrutinib
Participants with relapsed/refractory CLL received tirabrutinib 160 mg once daily.
Drug: Tirabrutinib
Participants with relapsed/refractory CLL received tirabrutinib 320 mg once daily.
Drug: Tirabrutinib
Participants with relapsed/refractory CLL received tirabrutinib 400 mg once daily.
Drug: Tirabrutinib
Participants with relapsed/refractory CLL received tirabrutinib 500 mg once daily.
Drug: Tirabrutinib
Participants with relapsed/refractory CLL received tirabrutinib 600 mg once daily.
Drug: Tirabrutinib
Participants with relapsed/refractory CLL received tirabrutinib 300 mg twice daily.
Drug: Tirabrutinib
Participants with relapsed/refractory non-Hodgkin's lymphoma (NHL) received tirabrutinib 20 mg once daily.
Drug: Tirabrutinib
Participants with relapsed/refractory NHL received tirabrutinib 40 mg once daily.
Drug: Tirabrutinib
Participants with relapsed/refractory NHL received tirabrutinib 80 mg once daily.
Drug: Tirabrutinib
Participants with relapsed/refractory NHL received tirabrutinib 160 mg once daily.
Drug: Tirabrutinib
Participants with relapsed/refractory NHL received tirabrutinib 320 mg once daily.
Drug: Tirabrutinib
Participants with relapsed/refractory NHL received tirabrutinib 480 mg once daily.
Drug: Tirabrutinib
Participants with relapsed/refractory NHL received tirabrutinib 600 mg once daily.
Drug: Tirabrutinib
Participants with relapsed/refractory NHL received tirabrutinib 240 mg twice daily.
Drug: Tirabrutinib
Capsules administered orally
Also known as: ONO/GS-4059
Percentage of Participants Experiencing Dose-Limiting Toxicities
Dose Limiting Toxicities (DLT) were defined as follows: * All Common Terminology Criteria (CTC) Grade 4 tirabrutinib related adverse events * All CTC Grade 3 tirabrutinib related adverse events, with the exception of the following: * CTC Grade 3 lymphocytosis considered an expected outcome of therapy Any toxicity which in the opinion of the Investigator is attributed to a participant's underlying disease was not considered a DLT.
Time frame: Day 1 through Day 28
Overall Response Rate
Overall response rate (ORR) was defined as the percentage of participants who achieve a best overall response of complete remission (CR, unconfirmed complete response (CRu), complete response with incomplete marrow recovery (CRi)) or partial remission (PR, nodal PR) during study as assessed by the investigator. ORR assessment was defined per following standardized criteria: * NHL: Cheson, 1999 * CLL: International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008
Time frame: Up to Cycle 37 (28 days for each cycle) plus 6-month intervals thereafter until disease progression (maximum: up to 39 months)
Pharmacokinetic (PK) Parameter: Cmax of Tirabrutinib
Cmax is defined as the maximum concentration of drug.
Time frame: Pre-dose, then 30 minutes, 1, 2, 3, 4, 6, 8, 12 hours post-dose at Cycle 1, Day 28
PK Parameter: AUCtau of Tirabrutinib
AUCtau is defined as concentration of drug over dosing interval.
Time frame: Pre-dose, then 30 minutes, 1, 2, 3, 4, 6, 8, 12 hours post-dose at Cycle 1, Day 28
Participants were enrolled at study sites in Europe. The first participant was screened on 17 August 2012. The last study visit occurred on 11 January 2016.
| Milestone | Tirabrutinib 20 mg Once Daily (CLL) | Tirabrutinib 40 mg Once Daily (CLL) | Tirabrutinib 80 mg Once Daily (CLL) | Tirabrutinib 160 mg Once Daily (CLL) | Tirabrutinib 320 mg Once Daily (CLL) | Tirabrutinib 400 mg Once Daily (CLL) | Tirabrutinib 500 mg Once Daily (CLL) | Tirabrutinib 600 mg Once Daily (CLL) | Tirabrutinib 300 mg Twice Daily (CLL) | Tirabrutinib 20 mg Once Daily (NHL) | Tirabrutinib 40 mg Once Daily (NHL) | Tirabrutinib 80 mg Once Daily (NHL) | Tirabrutinib 160 mg Once Daily (NHL) | Tirabrutinib 320 mg Once Daily (NHL) | Tirabrutinib 480 mg Once Daily (NHL) | Tirabrutinib 600 mg Once Daily (NHL) | Tirabrutinib 240 mg Twice Daily (NHL) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 3 | 3 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 5 | 8 | 21 | 10 | 9 | 3 |
| Completed | 1 | 2 | 4 | 3 | 3 | 2 | 1 | 1 | 2 | 0 | 0 | 1 | 0 | 3 | 2 | 4 | 0 |
| Not completed | 2 | 1 | 0 | 0 | 0 | 1 | 2 | 2 | 1 | 3 | 3 | 4 | 8 | 18 | 8 | 5 | 3 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 2 | 0 | 1 | 0 |
| Withdrew: Death | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 2 | 1 | 0 |
| Withdrew: Progressive disease | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 2 | 3 | 5 | 13 | 6 | 2 | 3 |
| Withdrew: Withdrew consent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Investigator decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Sponsor's decision | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Completed treatment per protocol at the time | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Participant went on to have an allograft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
Dose Limiting Toxicities (DLT) were defined as follows: * All Common Terminology Criteria (CTC) Grade 4 tirabrutinib related adverse events * All CTC Grade 3 tirabrutinib related adverse events, with the exception of the following: * CTC Grade 3 lymphocytosis considered an expected outcome of therapy Any toxicity which in the opinion of the Investigator is attributed to a participant's underlying disease was not considered a DLT.
| percentage of participants | Tirabrutinib 20 mg Once Daily (CLL) | Tirabrutinib 40 mg Once Daily (CLL) | Tirabrutinib 80 mg Once Daily (CLL) | Tirabrutinib 160 mg Once Daily (CLL) | Tirabrutinib 320 mg Once Daily (CLL) | Tirabrutinib 400 mg Once Daily (CLL) | Tirabrutinib 500 mg Once Daily (CLL) | Tirabrutinib 600 mg Once Daily (CLL) | Tirabrutinib 300 mg Twice Daily (CLL) | Tirabrutinib 20 mg Once Daily (NHL) | Tirabrutinib 40 mg Once Daily (NHL) | Tirabrutinib 80 mg Once Daily (NHL) | Tirabrutinib 160 mg Once Daily (NHL) | Tirabrutinib 320 mg Once Daily (NHL) | Tirabrutinib 480 mg Once Daily (NHL) | Tirabrutinib 600 mg Once Daily (NHL) | Tirabrutinib 240 mg Twice Daily (NHL) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Experiencing Dose-Limiting Toxicities | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 33.3 | 0.0 | 0.0 | 33.3 | 0.0 | 0.0 | 0.0 | 0.0 | 4.8 | 10.0 | 22.2 | 0.0 |
Overall response rate (ORR) was defined as the percentage of participants who achieve a best overall response of complete remission (CR, unconfirmed complete response (CRu), complete response with incomplete marrow recovery (CRi)) or partial remission (PR, nodal PR) during study as assessed by the investigator. ORR assessment was defined per following standardized criteria: * NHL: Cheson, 1999 * CLL: International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008
| percentage of participants | Chronic Lymphocytic Leukaemia | NHL Subtype FL | NHL Subtype SLL | NHL Subtype WM | NHL Subtype MZL | NHL Subtype DLBCL | NHL Subtype MCL |
|---|---|---|---|---|---|---|---|
| Overall Response Rate | 85.7 | 0.0 | 0.0 | 33.3 | 50.0 | 31.4 | 68.8 |
Cmax is defined as the maximum concentration of drug.
| ng/mL | Tirabrutinib 20 mg Once Daily (CLL or NHL) | Tirabrutinib 40 mg Once Daily (CLL or NHL) | Tirabrutinib 80 mg Once Daily (CLL or NHL) | Tirabrutinib 160 mg Once Daily (CLL or NHL) | Tirabrutinib 320 mg Once Daily (CLL or NHL) | Tirabrutinib 400 mg Once Daily (CLL) | Tirabrutinib 480 mg Once Daily (NHL) | Tirabrutinib 500 mg Once Daily (CLL) | Tirabrutinib 600 mg Once Daily (CLL or NHL) | Tirabrutinib 240 mg Twice Daily (NHL) | Tirabrutinib 300 mg Twice Daily (CLL) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmacokinetic (PK) Parameter: Cmax of Tirabrutinib | 73.4 ± 18.26 | 164.5 ± 47.22 | 241 ± 90.68 | 539.6 ± 141.58 | 1181.6 ± 380.39 | 826.5 ± 499.92 | 1240.3 ± 516.99 | 1230 ± 285.83 | 1265.2 ± 486.21 | 704.3 ± 254.51 | 674.3 ± 93.78 |
AUCtau is defined as concentration of drug over dosing interval.
| h*ng/mL | Tirabrutinib 20 mg Once Daily (CLL or NHL) | Tirabrutinib 40 mg Once Daily (CLL or NHL) | Tirabrutinib 80 mg Once Daily (CLL or NHL) | Tirabrutinib 160 mg Once Daily (CLL or NHL) | Tirabrutinib 320 mg Once Daily (CLL or NHL) | Tirabrutinib 400 mg Once Daily (CLL) | Tirabrutinib 480 mg Once Daily (NHL) | Tirabrutinib 500 mg Once Daily (CLL) | Tirabrutinib 600 mg Once Daily (CLL or NHL) | Tirabrutinib 240 mg Twice Daily (NHL) | Tirabrutinib 300 mg Twice Daily (CLL) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PK Parameter: AUCtau of Tirabrutinib | 306.4 ± 74.92 | 660.1 ± 310.95 | 762 ± 374.94 | 2681.8 ± 1055.17 | 5664.8 ± 1829.07 | 5259.5 ± 3166.57 | 7999.8 ± 2006.19 | 6766.9 ± 1025.64 | 8442.2 ± 2499.22 | 3415.5 ± 1296.47 | 3297.2 ± 1330 |
Collected over Adverse Events: First dose date up to the last dose date plus 30 days (maximum: 36 months); All-Cause Mortality: First dose date up to 39 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Chronic Lymphocytic Leukaemia | 5/28 (17.9%) | 17/28 (60.7%) | 28/28 (100%) |
| Non-Hodgkin's Lymphoma | 38/62 (61.3%) | 23/62 (37.1%) | 55/62 (88.7%) |
| Event | Chronic Lymphocytic Leukaemia | Non-Hodgkin's Lymphoma |
|---|---|---|
| Lower respiratory tract infectionInfections and infestations | 4/28 | 3/62 |
| PyrexiaGeneral disorders | 3/28 | 1/62 |
| Febrile neutropeniaBlood and lymphatic system disorders | 2/28 | 1/62 |
| Neutropenic sepsisInfections and infestations | 2/28 | 0/62 |
| Lymphocytic infiltrationBlood and lymphatic system disorders | 1/28 | 0/62 |
| NeutropeniaBlood and lymphatic system disorders | 1/28 | 0/62 |
| Spontaneous haematomaBlood and lymphatic system disorders | 1/28 | 0/62 |
| Inguinal hernia strangulatedGastrointestinal disorders | 1/28 | 0/62 |
| Abdominal abscessInfections and infestations | 1/28 | 0/62 |
| BacteraemiaInfections and infestations | 1/28 | 0/62 |
| Event | Chronic Lymphocytic Leukaemia | Non-Hodgkin's Lymphoma |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 9/28 | 23/62 |
| ContusionInjury, poisoning and procedural complications | 10/28 | 8/62 |
| NeutropeniaBlood and lymphatic system disorders | 9/28 | 9/62 |
| NasopharyngitisInfections and infestations | 9/28 | 11/62 |
| ThrombocytopeniaBlood and lymphatic system disorders | 4/28 | 18/62 |
| DiarrhoeaGastrointestinal disorders | 6/28 | 18/62 |
| FallInjury, poisoning and procedural complications | 8/28 | 5/62 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 8/28 | 5/62 |
| CoughRespiratory, thoracic and mediastinal disorders | 8/28 | 9/62 |
| PyrexiaGeneral disorders | 7/28 | 7/62 |
The Full Analysis Set included all the participants who received at least 1 dose of study drug.
| Age, Customized(Participants) | Tirabrutinib 20 mg Once Daily (CLL) | Tirabrutinib 40 mg Once Daily (CLL) | Tirabrutinib 80 mg Once Daily (CLL) | Tirabrutinib 160 mg Once Daily (CLL) | Tirabrutinib 320 mg Once Daily (CLL) | Tirabrutinib 400 mg Once Daily (CLL) | Tirabrutinib 500 mg Once Daily (CLL) | Tirabrutinib 600 mg Once Daily (CLL) | Tirabrutinib 300 mg Twice Daily (CLL) | Tirabrutinib 20 mg Once Daily (NHL) | Tirabrutinib 40 mg Once Daily (NHL) | Tirabrutinib 80 mg Once Daily (NHL) | Tirabrutinib 160 mg Once Daily (NHL) | Tirabrutinib 320 mg Once Daily (NHL) | Tirabrutinib 480 mg Once Daily (NHL) | Tirabrutinib 600 mg Once Daily (NHL) | Tirabrutinib 240 mg Twice Daily (NHL) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| < 65 years | 1 | 0 | 3 | 1 | 1 | 2 | 2 | 1 | 0 | 0 | 2 | 3 | 7 | 7 | 6 | 2 | 1 | 39 |
| ≥ 65 years | 2 | 3 | 1 | 2 | 2 | 1 | 1 | 2 | 3 | 3 | 1 | 2 | 1 | 14 | 4 | 7 | 2 | 51 |
| Sex: Female, Male(Participants) | Tirabrutinib 20 mg Once Daily (CLL) | Tirabrutinib 40 mg Once Daily (CLL) | Tirabrutinib 80 mg Once Daily (CLL) | Tirabrutinib 160 mg Once Daily (CLL) | Tirabrutinib 320 mg Once Daily (CLL) | Tirabrutinib 400 mg Once Daily (CLL) | Tirabrutinib 500 mg Once Daily (CLL) | Tirabrutinib 600 mg Once Daily (CLL) | Tirabrutinib 300 mg Twice Daily (CLL) | Tirabrutinib 20 mg Once Daily (NHL) | Tirabrutinib 40 mg Once Daily (NHL) | Tirabrutinib 80 mg Once Daily (NHL) | Tirabrutinib 160 mg Once Daily (NHL) | Tirabrutinib 320 mg Once Daily (NHL) | Tirabrutinib 480 mg Once Daily (NHL) | Tirabrutinib 600 mg Once Daily (NHL) | Tirabrutinib 240 mg Twice Daily (NHL) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 2 | 1 | 0 | 1 | 8 | 3 | 3 | 2 | 25 |
| Male | 3 | 3 | 3 | 2 | 2 | 3 | 3 | 2 | 2 | 1 | 2 | 5 | 7 | 13 | 7 | 6 | 1 | 65 |
| Race/Ethnicity, Customized(Participants) | Tirabrutinib 20 mg Once Daily (CLL) | Tirabrutinib 40 mg Once Daily (CLL) | Tirabrutinib 80 mg Once Daily (CLL) | Tirabrutinib 160 mg Once Daily (CLL) | Tirabrutinib 320 mg Once Daily (CLL) | Tirabrutinib 400 mg Once Daily (CLL) | Tirabrutinib 500 mg Once Daily (CLL) | Tirabrutinib 600 mg Once Daily (CLL) | Tirabrutinib 300 mg Twice Daily (CLL) | Tirabrutinib 20 mg Once Daily (NHL) | Tirabrutinib 40 mg Once Daily (NHL) | Tirabrutinib 80 mg Once Daily (NHL) | Tirabrutinib 160 mg Once Daily (NHL) | Tirabrutinib 320 mg Once Daily (NHL) | Tirabrutinib 480 mg Once Daily (NHL) | Tirabrutinib 600 mg Once Daily (NHL) | Tirabrutinib 240 mg Twice Daily (NHL) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| White | 2 | 3 | 4 | 1 | 3 | 3 | 2 | 3 | 2 | 3 | 3 | 3 | 7 | 16 | 9 | 8 | 3 | 75 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 2 |
| Other | 1 | 0 | 0 | 2 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 2 | 1 | 4 | 1 | 0 | 0 | 13 |
Ran from Aug 2012 to primary completion in Feb 2015, 30 months.
Results were first posted in Jan 2021, 5 years 11 months after primary completion.
Of 163 industry-sponsored phase 1 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 70. This study's 30 months is below that.
Counting every sponsor, half of 286 studies reached it within 55 months; a quarter within 38 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tirabrutinib